[HTML][HTML] COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
G Botti, F Fratangelo, M Cerrone, G Liguori… - Journal of Translational …, 2017 - Springer
Background The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have
prompted investigators to implement novel clinical trials which combine immunotherapy with …
prompted investigators to implement novel clinical trials which combine immunotherapy with …
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
G Botti, F Fratangelo, M Cerrone, G Liguori… - JOURNAL OF …, 2017 - iris.unisa.it
Background: The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have
prompted investigators to implement novel clinical trials which combine immunotherapy with …
prompted investigators to implement novel clinical trials which combine immunotherapy with …
[PDF][PDF] COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
G Botti, F Fratangelo, M Cerrone, G Liguori, M Cantile… - 2017 - iris.unina.it
Background: The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have
prompted investigators to implement novel clinical trials which combine immunotherapy with …
prompted investigators to implement novel clinical trials which combine immunotherapy with …
[引用][C] COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
G Botti, F Fratangelo, M Cerrone, G Liguori… - Journal of Translational …, 2017 - cir.nii.ac.jp
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
G Botti, F Fratangelo, M Cerrone… - Journal of …, 2017 - search.proquest.com
Background The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have
prompted investigators to implement novel clinical trials which combine immunotherapy with …
prompted investigators to implement novel clinical trials which combine immunotherapy with …
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
G Botti, F Fratangelo, M Cerrone… - Journal of …, 2017 - pubmed.ncbi.nlm.nih.gov
Background The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have
prompted investigators to implement novel clinical trials which combine immunotherapy with …
prompted investigators to implement novel clinical trials which combine immunotherapy with …
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
G Botti, F Fratangelo, M Cerrone, G Liguori… - Journal of Translational …, 2017 - infona.pl
Background The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have
prompted investigators to implement novel clinical trials which combine immunotherapy with …
prompted investigators to implement novel clinical trials which combine immunotherapy with …
[PDF][PDF] COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
G Botti, F Fratangelo, M Cerrone, G Liguori, M Cantile… - 2017 - academia.edu
Background: The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have
prompted investigators to implement novel clinical trials which combine immunotherapy with …
prompted investigators to implement novel clinical trials which combine immunotherapy with …
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
G Botti, F Fratangelo, M Cerrone, G Liguori… - Journal of …, 2017 - go.gale.com
Background The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have
prompted investigators to implement novel clinical trials which combine immunotherapy with …
prompted investigators to implement novel clinical trials which combine immunotherapy with …
[PDF][PDF] COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
G Botti, F Fratangelo, M Cerrone, G Liguori, M Cantile… - 2017 - cyberleninka.org
Background: The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have
prompted investigators to implement novel clinical trials which combine immunotherapy with …
prompted investigators to implement novel clinical trials which combine immunotherapy with …